

Jannis Kountouras

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/698159/publications.pdf>

Version: 2024-02-01

236
papers

7,114
citations

70961

41
h-index

69108

77
g-index

238
all docs

238
docs citations

238
times ranked

7526
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of spironolactone on pharmacological treatment of nonalcoholic fatty liver disease. <i>Minerva Endocrinology</i> , 2023, 48, .	0.6	2
2	Correspondence on 'Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis' by Rizos <i>et al</i> . <i>Heart</i> , 2022, 108, 657.1-657.	1.2	3
3	Ofeleelin i mi Vlapinâ€™ Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic. <i>Medicina (Lithuania)</i> , 2022, 58, 309.	0.8	4
4	GMâ€™CSF as a potential candidate of a vaccineâ€™induced reduction of <i>Helicobacter pylori</i> infection. <i>Helicobacter</i> , 2022, 27, e12884.	1.6	0
5	Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 852-862.	0.6	7
6	Impact of <i>Helicobacter pylori</i> -related metabolic syndrome with hyperhomocysteinemia on extragastric pathologies. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 407-408.	1.4	2
7	Cilofexor for the Treatment of Nonalcoholic Steatohepatitis. <i>Current Vascular Pharmacology</i> , 2022, 20, 111-113.	0.8	3
8	Letter to the Editor Regarding â€™The Association of <i>Helicobacter pylori</i> , Eradication, and Early Complications of Laparoscopic Sleeve Gastrectomyâ€™ by Abeid <i>et al.</i> . <i>Obesity Surgery</i> , 2022, 32, 2079.	1.1	2
9	<i>Helicobacter pylori</i> , gastric microbiota and gastric cancer relationship: Unrolling the tangle. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 959-972.	0.8	17
10	Comments on â€™dose-related meta-analysis for omega-3 fatty acids supplementation on major adverse cardiovascular eventsâ€™. <i>Clinical Nutrition</i> , 2022, , .	2.3	1
11	Alzheimerâ€™s disease and gastrointestinal microbiota; impact of <i>Helicobacter pylori</i> infection involvement. <i>International Journal of Neuroscience</i> , 2021, 131, 289-301.	0.8	38
12	Update on the association between nonâ€™alcoholic fatty liver disease and <i>Helicobacter pylori</i> infection. <i>International Journal of Clinical Practice</i> , 2021, 75, e13737.	0.8	6
13	<i>Helicobacter pylori</i> , Sleeve Gastrectomy, and Gastroesophageal Reflux Disease: Is There a Relation?. <i>Obesity Surgery</i> , 2021, 31, 1839-1840.	1.1	3
14	The impact of COVID-19 pandemic on gastrointestinal diseases: a single-center cross-sectional study in central Greece. <i>Annals of Gastroenterology</i> , 2021, 34, 323-330.	0.4	4
15	A potential impact of <i>Helicobacter pylori</i> -related sarcopenia on severity of portal hypertension. <i>Liver International</i> , 2021, 41, 1168-1169.	1.9	2
16	Does COVID-19 Vaccination Warrant the Classical Principle â€™ofeleelin i mi vlapinâ€™?. <i>Medicina (Lithuania)</i> , 2021, 57, 253.	0.8	10
17	The trimebutine effect on <i>Helicobacter pylori</i> -related gastrointestinal tract and brain disorders: A hypothesis. <i>Neurochemistry International</i> , 2021, 144, 104938.	1.9	9
18	<i>Helicobacter pylori</i> infection and diabetes mellitus. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 845-846.	1.8	4

#	ARTICLE	IF	CITATIONS
19	Potential impact of <i>Helicobacter pylori</i> -related metabolic syndrome and Galectin-3 on liver, chronic kidney and brain disorders. <i>Metabolism: Clinical and Experimental</i> , 2021, 118, 154736.	1.5	6
20	Irisin in nonalcoholic fatty liver disease: need for an updated meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2021, 121, 154818.	1.5	2
21	<i>Helicobacter pylori</i> -Related Metabolic Parameters and Premalignant Gastric Mucosa Histological Lesions in Swiss Bariatric Patients. <i>Microorganisms</i> , 2021, 9, 1361.	1.6	11
22	Impact of <i>Helicobacter pylori</i> -related Metabolic Syndrome and Gastroesophageal Reflux Disease on the Risk of Acute Myocardial Infarction. <i>Journal of Neurogastroenterology and Motility</i> , 2021, 27, 147-148.	0.8	3
23	Impact of <i>Helicobacter pylori</i> -related Microbial Dysbiosis in the Pathogenesis of Metabolic Syndrome and Gastrointestinal Dysmotility Disorders. <i>Journal of Neurogastroenterology and Motility</i> , 2021, 27, 653-654.	0.8	0
24	Impact of Body Mass Index on the Age of Relapsing-Remitting Multiple Sclerosis Onset: A Retrospective Study. <i>Neurology International</i> , 2021, 13, 517-526.	1.3	3
25	Role of autophagy in gastric carcinogenesis. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1244-1262.	0.8	5
26	Impact of <i>Helicobacter pylori</i> -Related Metabolic Syndrome Parameters on Arterial Hypertension. <i>Microorganisms</i> , 2021, 9, 2351.	1.6	21
27	Selenium and selenoprotein P in nonalcoholic fatty liver disease. <i>Hormones</i> , 2020, 19, 61-72.	0.9	30
28	<i>Helicobacter pylori</i> eradication regimens in an antibiotic high-resistance European area: A cost-effectiveness analysis. <i>Helicobacter</i> , 2020, 25, e12666.	1.6	12
29	Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e390-e400.	1.8	29
30	Impact of nitric oxide's bidirectional role on glaucoma: focus on <i>Helicobacter pylori</i> -related nitrosative stress. <i>Annals of the New York Academy of Sciences</i> , 2020, 1465, 10-28.	1.8	8
31	Influence of <i>Helicobacter pylori</i> -connected metabolic syndrome on non-alcoholic fatty liver disease and its related colorectal neoplasm high risk. <i>Liver International</i> , 2020, 40, 475-476.	1.9	11
32	Potential impact of <i>Helicobacter pylori</i> -related Galectin-3 on chronic kidney, cardiovascular and brain disorders in decompensated cirrhosis. <i>Digestive and Liver Disease</i> , 2020, 52, 121-123.	0.4	12
33	Potential Impact of <i>Helicobacter pylori</i> Infection on Reflux Disease Sequence. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 200-201.	1.1	1
34	Letter: <i>Helicobacter pylori</i> in proton pump inhibitor-associated biliary disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 313-314.	1.9	0
35	Treatment of nonalcoholic fatty liver disease: from adult trials to perspectives in the management of children and adolescents. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 247-251.	0.9	7
36	P704 The biennial direct pharmaceutical costs per treatment with biologics for the inflammatory bowel disease in Greece: A comparative calculation study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S569-S571.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Trimebutine Maleate Monotherapy for Functional Dyspepsia: A Multicenter, Randomized, Double-Blind Placebo Controlled Prospective Trial. <i>Medicina (Lithuania)</i> , 2020, 56, 339.	0.8	9
38	Enriched MACK-3 following CHAI and MACK-3 for the noninvasive diagnosis of nonalcoholic steatohepatitis. <i>Annals of Hepatology</i> , 2020, 19, 579-580.	0.6	0
39	Reconsidering the "protective" hypothesis of <i>Helicobacter pylori</i> infection in eosinophilic esophagitis. <i>Annals of the New York Academy of Sciences</i> , 2020, 1481, 59-71.	1.8	12
40	<i>Helicobacter pylori</i> infection as a potential risk factor for multiple sclerosis. <i>Medical Hypotheses</i> , 2020, 143, 110135.	0.8	11
41	The role of endoscopic ultrasound elastography in differentiating focal liver lesions. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1408-1408.	0.8	1
42	Letter to the editor re: Li et al. (2020), "The potential role of bacteria in pancreatic cancer: A systematic review". <i>Carcinogenesis</i> , 2020, 41, 539-540.	1.3	0
43	Association between Active <i>Helicobacter pylori</i> Infection and Glaucoma: A Systematic Review and Meta-Analysis. <i>Microorganisms</i> , 2020, 8, 894.	1.6	21
44	Dissociating nonalcoholic steatohepatitis from hepatocellular carcinoma in obesity. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 73-76.	0.7	2
45	Evaluation of the Direct Economic Cost per Eradication Treatment Regimen against <i>Helicobacter pylori</i> Infection in Greece: Do National Health Policy-Makers Need to Care?. <i>Medicina (Lithuania)</i> , 2020, 56, 133.	0.8	3
46	Association between <i>Helicobacter pylori</i> infection and Guillain-Barré Syndrome: A meta-analysis. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13218.	1.7	21
47	Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns. <i>Metabolism: Clinical and Experimental</i> , 2020, 104, 154144.	1.5	30
48	Correlation of registered drug packs in Greece with Maastricht V/Florence and Hellenic <i>Helicobacter pylori</i> infection treatment consensuses: A poor or a proper match?. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 127, 6-7.	1.2	3
49	Impact of <i>Helicobacter pylori</i> -linked metabolic syndrome on nonalcoholic fatty liver disease and its connected atrial fibrillation risk. <i>Liver International</i> , 2020, 40, 2036-2037.	1.9	8
50	Active <i>Helicobacter pylori</i> Infection is Independently Associated with Nonalcoholic Steatohepatitis in Morbidly Obese Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 933.	1.0	48
51	A potential impact of <i>Helicobacter pylori</i> infection on minimal hepatic encephalopathy pathobiology. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 25, 405-412.	0.5	3
52	Rodent models of obesity. <i>Minerva Endocrinologica</i> , 2020, 45, 243-263.	1.7	20
53	National consensus on <i>Helicobacter pylori</i> infection: the next-day challenge. <i>Annals of Gastroenterology</i> , 2020, 33, 324-325.	0.4	0
54	Letter: <i>Helicobacter pylori</i> infection and its role in oesophageal adenocarcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1215-1216.	1.9	0

#	ARTICLE	IF	CITATIONS
55	Homocysteine in nonalcoholic steatohepatitis: seemingly a paradox revisited. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 270-271.	0.5	4
56	Should the economic pillar be included in national, European or global consensus concerning <i>Helicobacter pylori</i> infection treatments?. <i>Annals of Gastroenterology</i> , 2020, 33, 326.	0.4	0
57	The therapeutic potential of C-C chemokine receptor antagonists in nonalcoholic steatohepatitis. <i>Exploration of Medicine</i> , 2020, 1, 170-183.	1.5	4
58	The Potential Role of Super Spread Events in SARS-COV-2 Pandemic; a Narrative Review. <i>Archives of Academic Emergency Medicine</i> , 2020, 8, e74.	0.2	5
59	A perspective on risk factors for esophageal adenocarcinoma: emphasis on <i>Helicobacter pylori</i> infection. <i>Annals of the New York Academy of Sciences</i> , 2019, 1452, 12-17.	1.8	26
60	Current Aspects on Differentiating Relapses from Over-Infections in Symptomatic Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2686-2687.	1.1	0
61	Asporin levels are low in patients with nonalcoholic fatty liver disease and increase after vitamin E treatment. <i>Hormones</i> , 2019, 18, 519-521.	0.9	8
62	Comparison of digital versus fiberoptic cholangioscopy in patients requiring evaluation of bile duct disease or treatment of biliary stones. <i>Annals of Gastroenterology</i> , 2019, 32, 178-184.	0.4	5
63	Comments to the Editor concerning the paper entitled "The microbiome and ophthalmic disease" by Baim et al.. <i>Experimental Biology and Medicine</i> , 2019, 244, 430-432.	1.1	5
64	The Effect of Trimebutine and/or <i>Helicobacter pylori</i> Eradication on the Gastroesophageal Reflux Disease, Irritable Bowel Syndrome, and Functional Dyspepsia Overlapping Disorders. <i>Journal of Neurogastroenterology and Motility</i> , 2019, 25, 473-474.	0.8	4
65	The relationship between <i>Helicobacter pylori</i> -related microbiota dysbiosis and gastrointestinal tract pathologies. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 806-807.	0.6	0
66	<i>Helicobacter pylori</i> infection and nonalcoholic fatty liver disease: Are the four meta-analyses favoring an intriguing association pointing to the right direction?. <i>Metabolism: Clinical and Experimental</i> , 2019, 96, iii-v.	1.5	16
67	<i>Helicobacter pylori</i> infection and gastrointestinal tract cancer biology: considering a double-edged sword reflection. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 2487-2488.	2.4	3
68	CHAI and MACK as noninvasive indices for nonalcoholic steatohepatitis. <i>Liver International</i> , 2019, 39, 1587-1587.	1.9	2
69	Metabolic syndrome components including high abdominal obesity and sarcopenia in patients with inflammatory bowel disease. <i>Annals of Gastroenterology</i> , 2019, 32, 214.	0.4	2
70	Impact of <i>Helicobacter pylori</i> and/or <i>Helicobacter pylori</i> -related metabolic syndrome on incidence of all-cause and Alzheimer's dementia. <i>Alzheimer's and Dementia</i> , 2019, 15, 723-725.	0.4	16
71	<i>Helicobacter pylori</i> infection and nonalcoholic fatty liver disease: Time for large clinical trials evaluating eradication therapy. <i>Helicobacter</i> , 2019, 24, e12588.	1.6	16
72	Acute Liver Failure. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 89-101.	1.1	9

#	ARTICLE	IF	CITATIONS
73	Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study. <i>Metabolism: Clinical and Experimental</i> , 2019, 101, 154005.	1.5	83
74	Vitamin D Deficiency and Unclear Abdominal Pain in Patients from Low- and Middle-Income Countries. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 4607.	1.2	2
75	Helicobacter pylori Infection: One More Contributor to Nonalcoholic Fatty Liver Disease Pathophysiology. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 624-626.	1.1	3
76	Selenoprotein P in Patients with Nonalcoholic Fatty Liver Disease. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 598-602.	0.6	18
77	Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. <i>Metabolism: Clinical and Experimental</i> , 2019, 92, 82-97.	1.5	679
78	Noninvasive Liver Fibrosis Tests in Patients with Nonalcoholic Fatty Liver Disease: An External Validation Cohort. <i>Hormone and Metabolic Research</i> , 2019, 51, 134-140.	0.7	32
79	Gastroesophageal reflux disease, irritable bowel syndrome and functional dyspepsia as overlapping conditions: focus on effect of trimebutine. <i>Annals of Gastroenterology</i> , 2019, 32, 318.	0.4	4
80	Molecular Links Between Alzheimer's Disease and Gastrointestinal Microbiota: Emphasis on Helicobacter pylori Infection Involvement. <i>Current Molecular Medicine</i> , 2019, 20, 3-12.	0.6	10
81	Microbes and Alzheimer' disease: lessons from H. pylori and GUT microbiota. <i>European Review for Medical and Pharmacological Sciences</i> , 2019, 23, 1845-1846.	0.5	9
82	Potential Impact of Helicobacter Pylori on Hepatic Encephalopathy Pathophysiology. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1087-1088.	1.1	3
83	Nonalcoholic fatty liver disease: Is it time for combination treatment and a diabetes-like approach?. <i>Hepatology</i> , 2018, 68, 389-389.	3.6	26
84	A potential impact of Helicobacter pylori -related galectin-3 in neurodegeneration. <i>Neurochemistry International</i> , 2018, 113, 137-151.	1.9	21
85	Comment on "Therapeutic Application of an Extract of Helicobacter pylori Ameliorates the Development of Allergic Airway Disease"; <i>Journal of Immunology</i> , 2018, 200, 3027.1-3027.	0.4	0
86	Irisin in metabolic diseases. <i>Endocrine</i> , 2018, 59, 260-274.	1.1	178
87	Review: Impact of <i>Helicobacter pylori</i> on Alzheimer's disease: What do we know so far?. <i>Helicobacter</i> , 2018, 23, e12454.	1.6	88
88	Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment. <i>Hormones</i> , 2018, 17, 573-579.	0.9	6
89	H. pylori and Parkinson's disease: Meta-analyses including clinical severity. <i>Clinical Neurology and Neurosurgery</i> , 2018, 175, 16-24.	0.6	78
90	Impact of <i>Helicobacter pylori</i> and/or <i>Helicobacter pylori</i> -related metabolic syndrome on gastroesophageal reflux disease-Barrett's esophagus-esophageal adenocarcinoma sequence. <i>Helicobacter</i> , 2018, 23, e12534.	1.6	10

#	ARTICLE	IF	CITATIONS
91	Helicobacter pylori Infection and Gastroesophageal Reflux Disease-Barrett's Esophagus-Esophageal Adenocarcinoma Sequence. American Journal of Gastroenterology, 2018, 113, 1723-1724.	0.2	6
92	Potential impact of Helicobacter pylori-related metabolic syndrome on upper and lower gastrointestinal tract oncogenesis. Metabolism: Clinical and Experimental, 2018, 87, 18-24.	1.5	53
93	Multiple Bidirectionality Brain-Gut Interactions in Patients With Inflammatory Bowel Disease. Gastroenterology, 2018, 155, 1651-1652.	0.6	6
94	The Emerging Role of Helicobacter Pylori-Induced Metabolic Gastrointestinal Dysmotility and Neurodegeneration. Current Molecular Medicine, 2018, 17, 389-404.	0.6	23
95	The impact of age on the incidence and severity of post-endoscopic retrograde cholangiopancreatography pancreatitis. Annals of Gastroenterology, 2018, 31, 96-101.	0.4	4
96	Potential Impact of Active Helicobacter pylori Infection with or without Concomitant Metabolic Syndrome on Colorectal Cancer Invasion and Mortality. Israel Medical Association Journal, 2018, 20, 725-726.	0.1	0
97	Helicobacter pylori-related chronic hepatitis C infection and the risk for cardiovascular disease. Liver International, 2017, 37, 1082-1082.	1.9	2
98	Impact of reactive oxygen species generation on Helicobacter pylori-related extragastric diseases: a hypothesis. Free Radical Research, 2017, 51, 73-79.	1.5	26
99	Helicobacter pylori eradication to prevent cardio-cerebrovascular disease: Are current data useful for clinical practice?. International Journal of Cardiology, 2017, 233, 92.	0.8	4
100	Helicobacter pylori related metabolic syndrome as predictor of progression to esophageal carcinoma in a subpopulation-based Barrett's esophagus cohort. Gastrointestinal Endoscopy, 2017, 85, 462-463.	0.5	7
101	Helicobacter pylori on portal hypertension-related hepatic encephalopathy. Immunopharmacology and Immunotoxicology, 2017, 39, 105-106.	1.1	1
102	Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: randomized controlled trial. Diabetes, Obesity and Metabolism, 2017, 19, 1805-1809.	2.2	41
103	Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota. Metabolism: Clinical and Experimental, 2017, 71, 182-197.	1.5	96
104	Novel aspects of defensins involvement in virus-induced autoimmunity in the central nervous system. Medical Hypotheses, 2017, 102, 33-36.	0.8	18
105	A potential impact of Helicobacter pylori infection on both obstructive sleep apnea and atrial fibrillation-related stroke. Sleep Medicine, 2017, 34, 256.	0.8	6
106	Letter: Helicobacter pylori -related non-alcoholic fatty liver disease with concomitant metabolic syndrome as risk factor for colorectal neoplasia. Alimentary Pharmacology and Therapeutics, 2017, 45, 576-577.	1.9	3
107	Obesity and the nervous system: more questions. Lancet Neurology, The, 2017, 16, 772-773.	4.9	1
108	Letter: Helicobacter pylori in lean and obese patients with non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2017, 46, 637-638.	1.9	3

#	ARTICLE	IF	CITATIONS
109	Circulating periostin in patients with nonalcoholic fatty liver disease. <i>Endocrine</i> , 2017, 56, 438-441.	1.1	6
110	Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR- β agonists. <i>Metabolism: Clinical and Experimental</i> , 2017, 66, 64-68.	1.5	17
111	Cardio-cerebrovascular disease and <i>Helicobacter pylori</i> -related metabolic syndrome: We consider eradication therapy as a potential cardio-cerebrovascular prevention strategy. <i>International Journal of Cardiology</i> , 2017, 229, 17-18.	0.8	36
112	<i>Helicobacter pylori</i> infection and esophageal adenocarcinoma: a review and a personal view. <i>Annals of Gastroenterology</i> , 2017, 31, 8-13.	0.4	33
113	Adipose tissue, obesity and non-alcoholic fatty liver disease. <i>Minerva Endocrinology</i> , 2017, 42, 92-108.	0.6	135
114	Active <i>Helicobacter pylori</i> Infection Is a Risk Factor for Colorectal Mucosa: Early and Advanced Colonic Neoplasm Sequence. <i>Gut and Liver</i> , 2017, 11, 733-734.	1.4	11
115	Comment on "Effect of biofilm formation by clinical isolates of <i>Helicobacter pylori</i> on the efflux-mediated resistance to commonly used antibiotics". <i>World Journal of Gastroenterology</i> , 2017, 23, 6194-6196.	1.4	16
116	Hepatic encephalopathy (HE) due to intrahepatic portosystemic shunt after total gastrectomy. <i>Digestive and Liver Disease</i> , 2016, 48, 825.	0.4	1
117	<i>Helicobacter pylori</i> infection and oesophageal adenocarcinoma. <i>Cancer Epidemiology</i> , 2016, 42, 206-207.	0.8	1
118	Colchicine to decrease inflammation and fibrosis in patients with metabolic dysregulation. <i>Medical Hypotheses</i> , 2016, 95, 34.	0.8	3
119	Activin A and follistatin in patients with nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1550-1558.	1.5	27
120	Homocysteine in nonalcoholic steatohepatitis: A reply. <i>European Journal of Internal Medicine</i> , 2016, 35, e40-e41.	1.0	0
121	Potential molecular aspects of <i>Helicobacter pylori</i> -related hyperplastic polyp development and progression. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 851-852.	0.8	0
122	Impact of <i>Helicobacter pylori</i> on multiple sclerosis-related clinically isolated syndrome. <i>Acta Neurologica Scandinavica</i> , 2016, 133, 268-275.	1.0	21
123	Adipokines in nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1062-1079.	1.5	250
124	Eosinophilic Enteritis Initially Presenting as Ampullary Stenosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, A19-A20.	2.4	3
125	Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease. <i>Journal of Bone and Mineral Metabolism</i> , 2016, 34, 447-456.	1.3	24
126	Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. <i>Diabetologia</i> , 2016, 59, 30-43.	2.9	186

#	ARTICLE	IF	CITATIONS
127	<i>Helicobacter pylori</i> -related ApoE 4 polymorphism may be associated with dysphagic symptoms in older adults. <i>Ecological Management and Restoration</i> , 2016, 29, 842-842.	0.2	11
128	ÂVaspin, resistin, retinol-binding protein-4, interleukin-1 β and interleukin-6 in patients with nonalcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2016, 15, 705-14.	0.6	24
129	A fully covered self-expandable metal stent anchored by a 10-Fr double pigtail plastic stent: an effective anti-migration technique. <i>Annals of Gastroenterology</i> , 2016, 30, 114-117.	0.4	8
130	Potential impact of <i>Helicobacter pylori</i> -related human β -defensin-1 on hepatic encephalopathy and neurodegeneration. <i>Annals of Gastroenterology</i> , 2016, 29, 99.	0.4	3
131	Factors predicting a positive capsule endoscopy in past overt obscure gastrointestinal bleeding: a multicenter retrospective study. <i>Hippokratia</i> , 2016, 20, 127-132.	0.3	7
132	Comment on "The correlation of <i>Helicobacter pylori</i> with the development of cholelithiasis and cholecystitis: the results of a prospective clinical study in Saudi Arabia". <i>European Review for Medical and Pharmacological Sciences</i> , 2016, 20, 3-4.	0.5	44
133	Novel Advances in the Association Between <i>Helicobacter pylori</i> Infection, Metabolic Syndrome, and Related Morbidity. <i>Helicobacter</i> , 2015, 20, 405-409.	1.6	22
134	Bone Marrow-Derived Stem Cells in Pathogenesis of <i>Helicobacter pylori</i> -Associated Gastrointestinal Cancer. <i>Clinical and Translational Gastroenterology</i> , 2015, 6, e129.	1.3	2
135	CD44 and <i>Helicobacter pylori</i> -related colon oncogenesis. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2015, 36, 1249-1249.	0.5	2
136	Nonalcoholic fatty liver disease and polycystic ovary syndrome. <i>Annals of Hepatology</i> , 2015, 14, 941-943.	0.6	3
137	Extragastric Diseases and <i>Helicobacter pylori</i> . <i>Helicobacter</i> , 2015, 20, 40-46.	1.6	150
138	<i>Helicobacter pylori</i> Associated With Obstructive Sleep Apnea Might Contribute to Sleep, Cognition, and Driving Performance Disturbances in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1547.	2.4	6
139	<i>Helicobacter pylori</i> might contribute to cancer and/or bone marrow-derived stem cell-related gastrointestinal oncogenesis. <i>Oncogene</i> , 2015, 34, 670-670.	2.6	4
140	The endoscopic morphology of major papillae influences the selected precut technique for biliary access. <i>Gastrointestinal Endoscopy</i> , 2015, 81, 1056.	0.5	9
141	Circulating homocysteine in nonalcoholic fatty liver disease. <i>European Journal of Internal Medicine</i> , 2015, 26, 152-153.	1.0	5
142	<i>Helicobacter pylori</i> infection, dementia and primary open-angle glaucoma: are they connected?. <i>BMC Ophthalmology</i> , 2015, 15, 24.	0.6	29
143	Association between cirrhosis and <i>Helicobacter pylori</i> -related brain pathologies. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 183.	0.8	4
144	Leptin in nonalcoholic fatty liver disease: A narrative review. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 60-78.	1.5	170

#	ARTICLE	IF	CITATIONS
145	Helicobacter Pylori-Related Vitamin B12 Deficiency: A Potential Contributor in Neuropsychiatric Disorders. Indian Journal of Psychological Medicine, 2015, 37, 475-476.	0.6	3
146	infection and gastroesophageal reflux disease - Barrett's esophagus sequence "dilemma". Annals of Gastroenterology, 2015, 28, 153.	0.4	7
147	Authors' reply. Annals of Gastroenterology, 2015, 28, 294-295.	0.4	0
148	Relationship between infection and multiple sclerosis. Annals of Gastroenterology, 2015, 28, 353-356.	0.4	19
149	The gut-brain axis: interactions between Helicobacter pylori and enteric and central nervous systems. Annals of Gastroenterology, 2015, 28, 506.	0.4	9
150	EFFECT OF HELICOBACTER PYLORI ERADICATION ON HEPATIC STEATOSIS, NAFLD FIBROSIS SCORE AND HSENSI IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS: a MR imaging-based pilot open-label study. Arquivos De Gastroenterologia, 2014, 51, 261-268.	0.3	30
151	Helicobacter pylori might contribute to nonalcoholic fatty liver disease-related cardiovascular events by releasing prothrombotic and proinflammatory factors. Hepatology, 2014, 60, 1450-1451.	3.6	15
152	Letter: low risk of colorectal cancer in a Greek cohort of inflammatory bowel disease patients. Alimentary Pharmacology and Therapeutics, 2014, 39, 1001-1002.	1.9	0
153	A possible impact of common worldwide environmental agents on the prognosis of critically ill cirrhotic patients. Liver International, 2014, 34, 1127-1128.	1.9	1
154	Body mass index and socioeconomic status measured in adolescence, country of origin, and the incidence of gastroesophageal adenocarcinoma in a cohort of 1 million men. Cancer, 2014, 120, 768-768.	2.0	2
155	Letter: apoptosis and hepatic fibrosis in chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 2014, 39, 996-996.	1.9	1
156	Association between Helicobacter pylori burden and Alzheimer's disease. European Journal of Neurology, 2014, 21, e100-e100.	1.7	9
157	Eradication of Helicobacter pylori infection might have a positive impact on subpopulations with endoscopic gastro-oesophageal reflux disease. European Journal of Gastroenterology and Hepatology, 2014, 26, 123.	0.8	1
158	Active Helicobacter pylori infection on colorectal mucosa "adenomatous polyp" adenocarcinoma sequence. European Journal of Gastroenterology and Hepatology, 2014, 26, 243-244.	0.8	5
159	Helicobacter pylori and Colorectal Cancer Risk"Letter. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 365-365.	1.1	4
160	Active Helicobacter pylori infection is associated with colorectal mucosa "adenomatous polyp" early and advanced adenocarcinoma sequence. Scandinavian Journal of Gastroenterology, 2014, 49, 381-382.	0.6	2
161	Irisin in patients with nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2014, 63, 207-217.	1.5	179
162	Impact of Helicobacter pylori infection on normal colorectal mucosa, adenomatous polyps and adenocarcinoma sequence. Colorectal Disease, 2014, 16, 390-391.	0.7	8

#	ARTICLE	IF	CITATIONS
163	Helicobacter pylori-related metabolic syndrome might justify earlier colorectal cancer screening. Gastrointestinal Endoscopy, 2014, 80, 188-189.	0.5	6
164	Helicobacter pylori infection, insulin resistance and nonalcoholic fatty liver disease. Medical Hypotheses, 2014, 82, 795.	0.8	7
165	Obstructive Sleep Apnea and Environmental Contributors for Barrett's Esophagus. Clinical Gastroenterology and Hepatology, 2014, 12, 1055-1056.	2.4	4
166	A proposed role of human defensins in Helicobacter pylori-related neurodegenerative disorders. Medical Hypotheses, 2014, 82, 368-373.	0.8	36
167	Additional data on Helicobacter pylori and hepatitis C virus infections and lymphoma association. European Journal of Internal Medicine, 2014, 25, e7-e8.	1.0	2
168	Risk factors for therapeutic ERCP-related complications: an analysis of 2,715 cases performed by a single endoscopist. Annals of Gastroenterology, 2014, 27, 65-72.	0.4	45
169	infection and liver cirrhosis: possible association with hepatic encephalopathy and/or post-hepatic encephalopathy cognitive impairment in patients with portal hypertension. Annals of Gastroenterology, 2014, 27, 285.	0.4	4
170	Patients with established gastro-esophageal reflux disease might benefit from eradication. Annals of Gastroenterology, 2014, 27, 352-356.	0.4	5
171	<i>Helicobacter pylori</i> Infection and Serum Adiponectin. Helicobacter, 2013, 18, 321-322.	1.6	6
172	Aquaporin 4, Helicobacter pylori and potential implications for neuromyelitis optica. Journal of Neuroimmunology, 2013, 263, 162-163.	1.1	7
173	Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2013, 62, 121-126.	1.5	130
174	<i>Helicobacter pylori</i> Infection and Insulin Resistance. Helicobacter, 2013, 18, 165-166.	1.6	12
175	Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index. Annals of Hepatology, 2013, 12, 749-757.	0.6	29
176	Innocent unilateral facial swelling after endoscopic sphincterotomy. Annals of Gastroenterology, 2013, 26, 93.	0.4	0
177	Serum visfatin in nonalcoholic fatty liver disease. Annals of Hepatology, 2013, 13, 150-1.	0.6	1
178	The Emerging Role of Endocrine Disruptors in Pathogenesis of Insulin Resistance: A Concept Implicating Nonalcoholic Fatty Liver Disease. Current Molecular Medicine, 2012, 12, 68-82.	0.6	85
179	Histological Presence of <i>Helicobacter pylori</i>; Bacteria in the Trabeculum and Iris of Patients with Primary Open-Angle Glaucoma. Ophthalmic Research, 2012, 47, 150-156.	1.0	44
180	Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology, 2012, 46, 272-284.	1.1	124

#	ARTICLE	IF	CITATIONS
181	<i>Helicobacter pylori</i> Infection Might Contribute to Esophageal Adenocarcinoma Progress in Subpopulations With Gastroesophageal Reflux Disease and Barrett's Esophagus. <i>Helicobacter</i> , 2012, 17, 402-403.	1.6	19
182	Trimebutine as a potential antimicrobial agent: a preliminary in vitro approach. <i>Hippokratia</i> , 2012, 16, 347-9.	0.3	6
183	A prospective analysis of factors influencing fluoroscopy time during therapeutic ERCP. <i>Annals of Gastroenterology</i> , 2012, 25, 338-344.	0.4	15
184	The Potential Adverse Role of Leptin Resistance in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 50-54.	1.1	69
185	The Association Between <i>Helicobacter pylori</i> Infection and Insulin Resistance: A Systematic Review. <i>Helicobacter</i> , 2011, 16, 79-88.	1.6	175
186	Double probe pH-monitoring findings in patients with benign lesions of the true vocal folds: comparison with typical GERD and the effect of smoking. <i>European Archives of Oto-Rhino-Laryngology</i> , 2011, 268, 1169-1174.	0.8	21
187	Eleven-year experience on the endoscopic treatment of post-cholecystectomy bile leaks. <i>Annals of Gastroenterology</i> , 2011, 24, 200-205.	0.4	10
188	The role of adiponectin in the pathogenesis and treatment of nonalcoholic fatty liver disease. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 365-383.	2.2	220
189	Five-year Survival After <i>Helicobacter pylori</i> Eradication in Alzheimer Disease Patients. <i>Cognitive and Behavioral Neurology</i> , 2010, 23, 199-204.	0.5	94
190	<i>Helicobacter pylori</i> : an intruder involved in conspiring glaucomatous neuropathy. <i>British Journal of Ophthalmology</i> , 2009, 93, 1413-1415.	2.1	40
191	Nonalcoholic Fatty Liver Disease: The Pathogenetic Roles of Insulin Resistance and Adipocytokines. <i>Current Molecular Medicine</i> , 2009, 9, 299-314.	0.6	270
192	Increased Cerebrospinal Fluid <i>Helicobacter Pylori</i> Antibody in Alzheimer's Disease. <i>International Journal of Neuroscience</i> , 2009, 119, 765-777.	0.8	96
193	Eradication of <i>Helicobacter pylori</i> may be beneficial in the management of Alzheimer's disease. <i>Journal of Neurology</i> , 2009, 256, 758-767.	1.8	150
194	<i>Helicobacter pylori</i> infection as a risk factor for primary open-angle glaucoma. <i>Clinical and Experimental Ophthalmology</i> , 2008, 36, 196-196.	1.3	12
195	Guillain-Barré syndrome. <i>Lancet Neurology</i> , The, 2008, 7, 1080-1081.	4.9	30
196	New Aspects of <i>Helicobacter pylori</i> Infection Involvement in Gastric Oncogenesis. <i>Journal of Surgical Research</i> , 2008, 146, 149-158.	0.8	62
197	New Aspects of Regulatory Signaling Pathways and Novel Therapies in Pancreatic Cancer. <i>Current Molecular Medicine</i> , 2008, 8, 12-37.	0.6	24
198	Recent advances in the management of radiation colitis. <i>World Journal of Gastroenterology</i> , 2008, 14, 7289.	1.4	84

#	ARTICLE	IF	CITATIONS
199	Helicobacter pylori may be involved in cognitive impairment and dementia development through induction of atrophic gastritis, vitamin B-12 folate deficiency, and hyperhomocysteinemia sequence. American Journal of Clinical Nutrition, 2007, 86, 805-806.	2.2	27
200	Alzheimer's disease and Helicobacter pylori infection: Defective immune regulation and apoptosis as proposed common links. Medical Hypotheses, 2007, 68, 378-388.	0.8	71
201	Eradication of Helicobacter pylori might halt the progress to oesophageal adenocarcinoma in patients with gastro-oesophageal reflux disease and Barrett's oesophagus. Medical Hypotheses, 2007, 68, 1174-1175.	0.8	14
202	Challenge in the Pathogenesis of Autoimmune Pancreatitis: Potential Role of Helicobacter pylori Infection via Molecular Mimicry. Gastroenterology, 2007, 133, 368-369.	0.6	54
203	Association between Helicobacter pylori infection and mild cognitive impairment. European Journal of Neurology, 2007, 14, 976-982.	1.7	74
204	Helicobacter pylori and gastro-oesophageal reflux disease. Lancet, The, 2006, 368, 986.	6.3	25
205	Relationship between Helicobacter pylori infection and Alzheimer disease. Neurology, 2006, 66, 938-940.	1.5	202
206	Association between Helicobacter pylori infection and acute inflammatory demyelinating polyradiculoneuropathy. European Journal of Neurology, 2005, 12, 139-143.	1.7	95
207	A concept on the role of Helicobacter pylori infection in autoimmune pancreatitis. Journal of Cellular and Molecular Medicine, 2005, 9, 196-207.	1.6	97
208	Apoptotic and anti-angiogenic strategies in liver and gastrointestinal malignancies. Journal of Surgical Oncology, 2005, 90, 249-259.	0.8	23
209	New concepts of molecular biology on gastric carcinogenesis. Hepato-Gastroenterology, 2005, 52, 1305-12.	0.5	10
210	Immunomodulatory benefits of cyclosporine A in inflammatory bowel disease. Journal of Cellular and Molecular Medicine, 2004, 8, 317-328.	1.6	28
211	Induction of apoptosis as a proposed pathophysiological link between glaucoma and Helicobacter pylori infection. Medical Hypotheses, 2004, 62, 378-381.	0.8	51
212	Apoptosis and autoimmunity as proposed pathogenetic links between Helicobacter pylori infection and idiopathic achalasia. Medical Hypotheses, 2004, 63, 624-629.	0.8	8
213	Primary open-angle glaucoma: pathophysiology and treatment. Lancet, The, 2004, 364, 1311-1312.	6.3	50
214	H pylori infection and reflux oesophagitis. Gut, 2004, 53, 912.	6.1	14
215	Increased levels of Helicobacter pylori IgG antibodies in aqueous humor of patients with primary open-angle and exfoliation glaucoma. Graefe's Archive for Clinical and Experimental Ophthalmology, 2003, 241, 884-890.	1.0	77
216	Apoptosis in hepatitis C. Journal of Viral Hepatitis, 2003, 10, 335-342.	1.0	90

#	ARTICLE	IF	CITATIONS
217	Helicobacter pylori and glaucoma. <i>Ophthalmology</i> , 2003, 110, 2433-2434.	2.5	13
218	Apoptosis, Inflammatory Bowel Disease and Carcinogenesis: Overview of International and Greek Experience. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2003, 17, 249-258.	1.8	29
219	Apoptosis in hepatocellular carcinoma. <i>Hepato-Gastroenterology</i> , 2003, 50, 242-9.	0.5	12
220	Locoregional immunochemotherapy in primary and metastatic liver disease: meta-analysis and review of literature. <i>Hepato-Gastroenterology</i> , 2003, 50, 1506-10.	0.5	0
221	Eradication of Helicobacter pylori May Be Beneficial in the Management of Chronic Open-Angle Glaucoma. <i>Archives of Internal Medicine</i> , 2002, 162, 1237.	4.3	103
222	Efficacy of trimebutine therapy in patients with gastroesophageal reflux disease and irritable bowel syndrome. <i>Hepato-Gastroenterology</i> , 2002, 49, 193-7.	0.5	15
223	Locoregional immunochemotherapy in hepatocellular carcinoma. <i>Hepato-Gastroenterology</i> , 2002, 49, 1109-12.	0.5	4
224	Relationship between Helicobacter pylori infection and glaucoma ¹¹ The authors have no commercial interests in the products or devices mention herein.. <i>Ophthalmology</i> , 2001, 108, 599-604.	2.5	130
225	Liver regeneration after hepatectomy. <i>Hepato-Gastroenterology</i> , 2001, 48, 556-62.	0.5	43
226	Reactive oxygen metabolites and upper gastrointestinal diseases. <i>Hepato-Gastroenterology</i> , 2001, 48, 743-51.	0.5	29
227	New epidemiological data on liver oncogenesis. <i>Hepato-Gastroenterology</i> , 2000, 47, 855-61.	0.5	9
228	New concepts of molecular biology for colon carcinogenesis. <i>Hepato-Gastroenterology</i> , 2000, 47, 1291-7.	0.5	11
229	Omeprazole and regulation of cytokine profile in Helicobacter pylori-infected patients with duodenal ulcer disease. <i>Hepato-Gastroenterology</i> , 2000, 47, 1301-4.	0.5	7
230	In vivo effect of granulocyte-macrophage colony-stimulating factor and interferon combination on monocyte-macrophage and T-lymphocyte functions in chronic hepatitis B leukocytopenic patients. <i>Hepato-Gastroenterology</i> , 1998, 45, 2295-302.	0.5	1
231	The effect of mannitol and secretin on the biliary transport of urate in humans. <i>Hepatology</i> , 1996, 23, 229-233.	3.6	12
232	The effect of mannitol and secretin on the biliary transport of urate in humans. <i>Hepatology</i> , 1996, 23, 229-233.	3.6	5
233	Recombinant $\alpha 2$ interferon (α -IFN) with chemo-hormonal therapy in patients with hepatocellular carcinoma (HCC). <i>Hepato-Gastroenterology</i> , 1995, 42, 31-6.	0.5	8
234	In Vivo Effect of Omeprazole on HLA-DR Expression and the Nonocyte-Macrophage Function in Patis with Duodenal Ulcer Disease. <i>Immunopharmacology and Immunotoxicology</i> , 1994, 16, 437-448.	1.1	7

#	ARTICLE	IF	CITATIONS
235	Value of ascitic fluid ferritin in the differential diagnosis of malignant ascites. <i>Anticancer Research</i> , 1993, 13, 2441-5.	0.5	6
236	Potential Impact of Active <i>H. pylori</i> Infection-Related Metabolic Syndrome on Preeclampsia Among Pregnant Women [Letter]. <i>International Journal of Women's Health</i> , 0, Volume 14, 845-846.	1.1	0